Evidence map›Paper›PMID 39757805›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2025

Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC Prevention.

Tsung-Che Wu, Chia-Chi Lin

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Tsung-Che WuDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-6927-9383
Chia-Chi LinDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-2573-5789

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study by Downs and colleagues targets patients with non-muscle-invasive bladder cancer (NMIBC) to explore secondary/tertiary cancer prevention strategies. Utilizing a "window-of-opportunity" design, erlotinib was evaluated for its effect on EGFR phosphorylation, although the unconventional dosing regimen failed to demonstrate efficacy. New opportunities in NMIBC prevention include targeting FGFR3 mutations with emerging FGFR inhibitors. A future trial design could focus on clinical outcomes such as tumor response and NMIBC recurrence while also evaluating FGFR3 inhibition in both tumor and adjacent normal bladder epithelia. See related article by Downs et al., p. 31.

Indexed as

ErbB ReceptorsProtein Kinase InhibitorsUrinary Bladder NeoplasmsErlotinib HydrochlorideHumansMutationNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsReceptor, Fibroblast Growth Factor, Type 3EGFR protein, humanErbB ReceptorsErlotinib HydrochlorideFGFR3 protein, humanProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 3

Identifiers

PMID39757805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.